For the Inventor, By the Inventor

Enter assignee name

Aubonne, Switzerland

Ares Trading S.a.

USPTO Granted Patents = 139

% Expired Patents = 36.7

CIPO Patents = 22

EPO Patents = 79

Trademarks = 28

Forward Citations = 1,656

Loading Chart...

Loading Chart...

265 inventors (with patents filed for the assignee):

Christine Power (10 out of 23 patents)

Alessandra Del Rio (9 out of 25 patents)

Richard Fagan (9 out of 9 patents)

4. Herve Broly (8 out of 8 patents)

5. Gerhard Lauchard (8 out of 9 patents)

6. Fabrizio Samaritani (8 out of 16 patents)

7. Werner Wurmbauer (7 out of 8 patents)

8. Christopher Benjamin Phelps (7 out of 8 patents)

9. Mara Rossi (6 out of 8 patents)

10. Martin Jordan (6 out of 9 patents)

11. Georgios Kouvas (6 out of 7 patents)

12. Vincent Pongpairochana (6 out of 7 patents)

13. Matthieu Stettler (5 out of 9 patents)

14. Charles A Dinarello (5 out of 45 patents)

15. Anna Quattropani (5 out of 58 patents)

Core Competencies:

Immunoassays

Protein Modulation

Injection Devices

Drug Formulations

Monoclonal Antibodies

FGF-18

Recombinant Proteins

Autoimmune Treatments

Liquid Formulations

Mannosylation

Therapeutics

139 patents: Sort by Forward Citations

1. 12661302 - Home stock management system (2026-06-23),

2. 12653994 - Microneedle array, actuator and method of use (2026-06-16),

3. 12650406 - Capillary gel electrophoresis and its use with complex biological molecules (2026-06-09),

4. 12474329 - IMMUNOASSAYS FOR HIGH POSITIVELY CHARGED PROTEINS (2025-11-18),

5. 12268703 - Cladribine regimen for treating progressive forms of multiple sclerosis (2025-04-08),

6. 11707508 - Anti-retroviral treatment using growth hormone (2023-07-25),

7. 11566062 - Methods for modulating protein mannosylation profiles using maduramycin, narasin, or salinomycin (2023-01-31),

8. 11559634 - Tip determiner for an injection device (2023-01-24),

9. 11538234 - Method and apparatus for determining information about a drug-containing vessel (2022-12-27),

10. 11494578 - Systems and methods for automated assessment of embryo quality using image based features (2022-11-08),

11. 11242372 - IFN beta protein analogs (2022-02-08),

12. 11118208 - Methods for modulating protein galactosylation profiles of recombinant proteins using peracetyl galactose (2021-09-14),

13. 11007328 - Medicine injection device with a pain-reduction member (2021-05-18),

14. 10959939 - Liquid pharmaceutical composition of etanercept with lysine and proline (2021-03-30),

15. 10942170 - Quantitative measurement of human blastocyst and morula morphology developmental kinetics (2021-03-09),

Company Overview

Ares Trading S.a., headquartered in Aubonne, Switzerland, specializes in biopharmaceutical innovations with a focus on developing advanced therapeutic solutions. The company is engaged in the research and production of immunoassays, protein modulation technologies, and drug formulations, particularly in the realm of monoclonal antibodies and recombinant proteins. Ares Trading is dedicated to addressing autoimmune conditions and enhancing treatment efficacy through innovative injection devices and targeted therapies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

139 Patents

#1 in Aubonne

#138 in Switzerland

#5,829 in the World

Aubonne, Switzerland

Ares Trading S.a.

Forward Citations = 1,656

265 inventors:

Christine Power (10 out of 23 patents)

Alessandra Del Rio (9 out of 25 patents)

Richard Fagan (9 out of 9 patents)

4. Herve Broly (8 out of 8 patents)

5. Gerhard Lauchard (8 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ares Trading S.a.. Retrieved from https://idiyas.com/company/ares-trading-s-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…